Cargando…
Therapeutic Advances in Diabetic Kidney Disease
Although sodium glucose co-transporter type 2 (SGLT-2) inhibitors were initially introduced as glucose-lowering medications, it was later discovered that cardiorenal protection is the most important treatment effect of these agents. A triad of landmark trials consistently showed the benefits of SGLT...
Autores principales: | Georgianos, Panagiotis I., Vaios, Vasilios, Eleftheriadis, Theodoros, Papachristou, Evangelos, Liakopoulos, Vassilios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917247/ https://www.ncbi.nlm.nih.gov/pubmed/36769113 http://dx.doi.org/10.3390/ijms24032803 |
Ejemplares similares
-
Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022) -
Hypertension in Dialysis Patients: Diagnostic Approaches and Evaluation of Epidemiology
por: Georgianos, Panagiotis I., et al.
Publicado: (2022) -
Should We Use Dialyzable β-Blockers in Hemodialysis?
por: Georgianos, Panagiotis I., et al.
Publicado: (2022) -
Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder
por: Yavropoulou, Maria P., et al.
Publicado: (2020) -
Oxidized LDL Modifies the Association between Proteinuria and Deterioration of Kidney Function in Proteinuric Diabetic Kidney Disease
por: Roumeliotis, Stefanos, et al.
Publicado: (2021)